Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 18/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.52 |
| ▸ | EZH1 | Q92800 | 1/20 | 0.45 |
| ▸ | EED | O75530 | 1/20 | 0.44 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.44 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.44 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19503283 | 0.85 | EZH2 (0.50) | EZH2HDAC1HDAC6EZH1EED | |
| SCHEMBL19503754 | 0.80 | EZH2 (0.56) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL19503276 | 0.76 | EZH2 (0.57) | EZH2HDAC1HDAC6EZH1EED | |
| SCHEMBL13277247 | 0.76 | EZH2 (1.00) | EZH2HDAC1HDAC6 | |
| SCHEMBL19503282 | 0.75 | EZH2 (0.51) | EZH2HDAC1HDAC6EZH1 | |
| SCHEMBL19503417 | 0.75 | EZH2 (0.49) | EZH2HDAC1HDAC6EZH1EED | |
| SCHEMBL15700591 | 0.74 | EZH2 (0.95) | EZH2HDAC1HDAC6 | |
| SCHEMBL19503275 | 0.74 | EZH2 (0.55) | EZH2HDAC1HDAC6EZH1EED | |
| SCHEMBL19503267 | 0.74 | EZH2 (0.71) | EZH2HDAC1HDAC6EZH1EED | |
| SCHEMBL19503335 | 0.73 | EZH2 (0.48) | EZH2HDAC1HDAC6EZH1EED |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10633371-B2 | EZH2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20200039968-A9 | EZH2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-20190135796-A1 | EZH2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| WO-2017184999-A1 | EZH2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135796-A1 | EZH2 INHIBITORS AND USES THEREOF | EZH2, EZH1, BMI1 | EZH2 1/4885HDAC1 20/4885HDAC6 109/4885 |
| US-20200039968-A9 | EZH2 INHIBITORS AND USES THEREOF | EZH2, EZH1, BMI1 | EZH2 1/4885HDAC1 20/4885HDAC6 109/4885 |
| US-10633371-B2 | EZH2 inhibitors and uses thereof | EZH2, EZH1, BMI1 | EZH2 1/4885HDAC1 20/4885HDAC6 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.